780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Abstract

BackgroundMultiple cancer immunotherapies of T-cell checkpoint inhibitors have been approved worldwide. However, most patients with advanced solid tumors do not benefit, or relapse after T-cell checkpoint blockade. Myeloid checkpoint inhibition...